Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)⢠Click on a phase to view related trials
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
- Conditions
- Overweight or Obesity
- Interventions
- Other: Matching Placebo
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06854952
- Locations
- đşđ¸
FALCON Research Site, Arlington, Virginia, United States
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
- Conditions
- Chronic Myeloid Leukemia, Chronic PhaseChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06163430
- Locations
- đşđ¸
UC Irvine Health, Orange, California, United States
đşđ¸Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
đşđ¸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT05415722
- Locations
- đşđ¸
Site 1017: The Institute for Liver Health dba Arizona Liver Health, Chandler, Arizona, United States
đşđ¸Site 1018: Arizona Liver Health, Tucson, Arizona, United States
đşđ¸Site 1004 Southern California Research Center, Coronado, California, United States
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04897594
- Locations
- đşđ¸
Terns Clinical Study Site 1018, Tucson, Arizona, United States
đşđ¸Terns Clinical Study Site 1024, Tucson, Arizona, United States
đşđ¸Terns Clinical Study Site 1004, Coronado, California, United States
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04328077
- Locations
- đşđ¸
Terns Clinical Study Site 1017, Chandler, Arizona, United States
đşđ¸Terns Clinical Study Site 1018, Tucson, Arizona, United States
đşđ¸Terns Clinical Study Site 1024, Tucson, Arizona, United States
News
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
⢠The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. ⢠This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. ⢠Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. ⢠The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.